KidKraft Announces Appointment of Todd Whitbeck as Chief Financial Officer
28.10.2019 12:00:00 EET | Business Wire | Press release
KidKraft, Inc. (“KidKraft”) announced today Todd Whitbeck, a seasoned executive with more than 30 years of experience in finance and corporate development, has been appointed Chief Financial Officer effective immediately.
Whitbeck has a proven track record of financial expertise and operational leadership across a diverse background of public and private companies, with previous success working with MidOcean Partners, the private equity firm that owns KidKraft. He will oversee global financial operations and work closely with KidKraft’s CEO on continued growth and international expansion as the company builds on a 50-year legacy in the toy and juvenile product industry. Whitbeck will report directly to Geoff Walker, Chief Executive Officer.
“Todd is a seasoned finance executive and his leadership will help drive KidKraft’s growth strategies,” said Geoff Walker, CEO, KidKraft. “I’m excited for his partnership and to welcome him as a key member of our executive team.”
“I look forward to working with Geoff and the team at KidKraft and to leveraging my prior experience to fuel the company’s growth,” said Todd Whitbeck. “Having worked across many industries throughout my career, it’s refreshing after all these years to work with a company that inspires the imaginations of children who will lead future generations.”
Whitbeck was most recently CFO and Head of Business Development, Sales, Marketing and Administrative Functions for CANarchy, a fast-growing collective of local, regional and national craft beer breweries. Previously he was Executive Vice President, CFO & Business Development for Water Pik, Inc. where he led and facilitated a very successful sale of the company, and subsequently led integration efforts for the combined companies. He was CFO for JP Energy, Sears Holdings Corporation (SHC) in the hard goods business units and off-mall retail selling formats, and CompUSA, where he elevated his oversight to CFO through various finance roles as the company grew and was acquired. He is a board member for Tufts Health Plan Board of Directors.
An industry leader in design and development of children’s toys and furniture, KidKraft is focused on inspiring imaginative play experiences through high quality products. The company's innovative portfolio includes dollhouses, play kitchens, outdoor playsets, children's furniture, wooden dolls and vehicles and more, offering a variety of different play experiences this holiday season. The company was acquired by MidOcean Partners (“MidOcean”), a premier middle market private equity firm focused on consumer and business services, in July 2015.
About KidKraft, Inc.
KidKraft is a global leader in award-winning products that are MADE FOR MAKE BELIEVE™. The company is committed to inspiring imaginative play creatively for children everywhere through dollhouses, kitchens, outdoor, vehicles, furniture, and toys. KidKraft’s high-quality products, designed for traditional play, are available at more than 2,800 retailers in more than 90 countries worldwide. KidKraft’s global headquarters are located in Dallas, Texas. For more information, visit www.kidkraft.com and follow @kidkrafttoys on Instagram.
About MidOcean Partners
MidOcean Partners is a premier New York-based alternative asset manager that specializes in middle market private equity and alternative credit investments. Since its inception in 2003, MidOcean Private Equity has managed approximately $4.8 billion of committed capital and has targeted investments in high-quality middle market companies in the consumer and business services sectors. MidOcean Credit Partners was launched in 2009 and manages approximately $8 billion across a series of alternative credit strategies, collateralized loan obligations (CLOs), and customized separately managed accounts as of September 30, 2019.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191028005062/en/
Contact information
Litzky Public Relations on behalf of KidKraft
Kelsey Wheeler
Litzky Public Relations
201/222-9118
kidkraft@litzkypr.com
MidOcean Media Relations
Nathaniel Garnick/Amanda Klein
Gasthalter & Co.
212/257-4170
midocean@gasthalter.com
MidOcean Investor Relations
Allison Donohue
Investorrelations@midoceanpartners.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom